Skip to main content
You have permission to edit this article.
Edit

Novavax says vaccine targeting Covid and flu shows promising results in early data

Novavax plans to move forward with a phase two trial this year to confirm the dosing levels, and a phase three during the 2023 flu season at the earliest.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.